2 completed, 1 not yet recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Not yet recruiting 1 |
Follow Cefiderocol: new trials by email Literature Review of Cefiderocol trials Research Report on Cefiderocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation Ceftazidime - Avibactam ( CAZ-AVI), Meropenem-Vaborbactam, Imipenem+Relebactam - Liver Transplant, Carbapenem-resistant Enterobacterales | Phase 3 | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 168 | 2026-10-01 | 2026-08-12 |
| Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens Cefiderocol, Meropenem, Linezolid - Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP) | Phase 3 | Completed | Shionogi | 300 | 2017-10-24 | 2020-11-13 |
| Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Cefiderocol, Best Available Therapy - Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI) | Phase 3 | Completed | Shionogi | 152 | 2016-09-07 | 2021-01-12 |
Healthcare-Associated Pneumonia (2) · Pneumonia, Ventilator-Associated (2) · Pneumonia (1) · Sepsis (1)
Shionogi (2) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1)
France (2) · Germany (2) · Israel (2) · Italy (2) · Japan (2) · Spain (2) · Taiwan (2) · United States (2) · Belgium (1) · Brazil (1) · Canada (1) · Croatia (1) · Czechia (1) · Estonia (1) · Georgia (1)
Maddalena Giannella, MD, PhD (1)
PMID 34792787, PMID 35076335, PMID 31819544, PMID 33058795, PMID 33058798, PMID 33393598, PMID 35025025
2015 (1), 2016 (1), 2025 (1)